Procaps Group Receives Notification From Nasdaq Notice Related To Late Filing Of Its Form 20-F

5/20/24 4:13:20 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PROC alert in real time by email

Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has received a letter from the Nasdaq Stock Market, dated May 16, 2024 (the "Delinquency Letter"), notifying the Company that it is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because it did not timely file its annual report on Form 20-F for the year ended December 31, 2023 (the "2023 20-F").

Get the next $PROC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PROC

Date	Price Target	Rating	Analyst

More analyst ratings

Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), announced today that, on November 13, 2024, the Company received formal notice from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's failure to timely file the Form 20-F for the fiscal year ended December 31, 2023 (the "Form 20-F") with the U.S. Securities and Exchange Commission (the "SEC"), the Company no longer satisfied Nasdaq Listing Rule 5250(c)(1) (the "Filing Rule") and its securities are therefore subject to suspension and delisting unless the Company timely requests a hearing
11/15/24 6:15:13 PM ET
$PROC
Biotechnology: Pharmaceutical Preparations
Health Care
Procaps Issues Shareholder Letter Update
MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, providing critical updates on the Company's ongoing independent investigation, financial restatement, governance enhancements, and commitment to long-term stability. "Dear Shareholders, As we navigate recent challenges at Procaps, I want to personally reaffirm our dedication to transparency, compliance, and sustainable management. We are committed to addressing the findings from our ongoing investigati
10/10/24 5:26:51 PM ET
$PROC
Biotechnology: Pharmaceutical Preparations
Health Care
Procaps Issues Shareholder Letter Update
MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, with updates on the Company's restructuring and strategic plan projects. "Dear Shareholders, We are pleased to update you on several significant developments as we continue to move forward with our strategic plan and financial restructuring efforts. Forbearance Agreements We have successfully signed consolidated forbearance agreements covering approximately an aggregate of $209 million in debt. These ag
9/18/24 8:10:00 AM ET
$PROC
Biotechnology: Pharmaceutical Preparations
Health Care

$PROC
Financials

Live finance-specific insights

Procaps Group Reports Third Quarter 2023 Results
Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended September 30, 2023 ("3Q23") and the nine months ended September 30, 2023 ("9M23"). Financial Highlights 3Q23 & 9M23 Net revenues totaled $118 million for 3Q23, positively impacted by the performance of RX and OTC portfolios, offset by lower CDMO revenues. On a constant currency basis, net revenues increased by 2% in 3Q23. For 9M23, net revenues totaled $313 million, an incre
12/26/23 5:40:00 PM ET
$PROC
Biotechnology: Pharmaceutical Preparations
Health Care
Procaps Group Update on Third Quarter Results
Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call. About Procaps Group Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplie
11/14/23 5:25:00 PM ET
$PROC
Biotechnology: Pharmaceutical Preparations
Health Care
Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023
Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023. The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results. To access the call, please use the following information: Date: Thursday, November 16, 2023 Time: 10:30 a.m. ET Webcast: Cli
11/10/23 11:37:00 AM ET
$PROC
Biotechnology: Pharmaceutical Preparations
Health Care

$PROC
Leadership Updates

Live Leadership Updates

Statement from the Board of Directors of Procaps Group
Procaps Group (NASDAQ:PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders. Throughout his career in the Organization,
12/21/23 6:45:00 PM ET
$PROC
Biotechnology: Pharmaceutical Preparations
Health Care
Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024
Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group. The transition will be effective January 15, 2024. After over 45 years of visionary leadership and dedicated service, Ruben Minski has played a pivotal role in Procaps' growth and success, transforming it into a global leader in pharmaceutical innovation. Under
11/22/23 8:30:00 AM ET
$PROC
Biotechnology: Pharmaceutical Preparations
Health Care
Procaps Appoints Sandra Sánchez y Oldenhage to Board of Directors
Experienced Pharma Professional Brings Wealth of International Industry and Governance Experience to Board Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced the appointment of one new member to its Board of Directors (the "Board"). On October 23, 2023, the Board appointed Sandra Sánchez y Oldenhage as a Director to fill the current vacancy on the Board, effective immediately and for a period ending at its annual general meeting of shareholders for the fiscal year ended December 31, 2023. Sandra Sánchez y Oldenhage has over 35 years' experience in steering mature, start-up, and turn-around/re
10/23/23 5:01:00 PM ET
$PROC
Biotechnology: Pharmaceutical Preparations
Health Care

Procaps Group Receives Notification From Nasdaq Notice Related To Late Filing Of Its Form 20-F

Chat with this insight

Recent Analyst Ratings for
$PROC

$PROC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

$PROC
SEC Filings

SEC Form 6-K filed by Procaps Group S.A.

SEC Form 6-K filed by Procaps Group S.A.

SEC Form 6-K filed by Procaps Group S.A.

$PROC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$PROC
Press Releases

Fastest customizable press release news feed in the world

SEC Form 3: New insider Manieu Alexandre Weinstein claimed ownership of 15,877,516 units of Ordinary Shares

SEC Form 3: New insider Minski Ruben claimed ownership of 31,338,454 units of Ordinary Shares

SEC Form 3: New insider Minski Jose claimed ownership of 17,960,146 units of Ordinary Shares

Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing

Procaps Issues Shareholder Letter Update

Procaps Issues Shareholder Letter Update

$PROC
Market Insights

Live Market Insights

Procaps Group Appoints José Minski As Chairman Of The Board